PH HEALTH announced FDA approval of its new generic application ANDA040105 on July 30, 1996, signaling the company's strategic entry into the branded or complex manufacturing sector during the mid-90s pharmaceutical market expansion. This regulatory milestone not only solidified PH HEALTH’s market position but also signaled the firm's capability to meet rigorous industry standards at the dawn of the modern supply chain.